Close Menu

NEW YORK – Novartis said Tuesday that the new drug application for its investigational MET inhibitor capmatinib (INC280) was accepted by the US Food and Drug Administration and granted priority review. Novartis expects the review to be completed within six months.

Capmatinib is currently being evaluated in untreated and previously treated patients with MET exon 14 skipping mutated advanced or metastatic non-small cell lung cancer. METex14 mutations tend to occur in 3 percent to 4 percent of newly diagnosed advanced NSCLC cases.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
17

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.